IPP Bureau
Pharma exports continue to climb in H1FY22
By IPP Bureau - October 19, 2021
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
Alcon announces launch of AcrySof IQ Vivity in India,
By IPP Bureau - October 19, 2021
It is the first presbyopia-correcting lens implant for cataract surgery
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
By IPP Bureau - October 19, 2021
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
MSN Labs launches drug for diabetes management
By IPP Bureau - October 19, 2021
The company claims that its Empagliflozin tablets are the most affordable in India
Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %
By IPP Bureau - October 19, 2021
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
.jpg "Luke Coutinho launches e-commerce venture YouCareLifestyle")
Luke Coutinho launches e-commerce venture YouCareLifestyle
By IPP Bureau - October 19, 2021
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
AstraZeneca ties up with Rajiv Gandhi Cancer Institute to treat patients with Chronic Lymphocytic Leukemia
By IPP Bureau - October 19, 2021
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
WHO to take call on Covaxin's EUL on October 26th
By IPP Bureau - October 18, 2021
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
By IPP Bureau - October 18, 2021
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Imfinzi plus tremelimumab significantly improved overall survival in liver cancer
By IPP Bureau - October 18, 2021
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
U.S. FDA advisory committee recommends J&J booster dose
By IPP Bureau - October 18, 2021
U.S. FDA to decide whether to authorize a booster dose in the coming days
Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
By IPP Bureau - October 18, 2021
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Resilience and Harvard announce five-year R&D alliance
By IPP Bureau - October 18, 2021
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
GPT Healthcare to go public to fund expansion
By IPP Bureau - October 18, 2021
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
Granules gets ANDA approval for Dofetilide capsules
By IPP Bureau - October 18, 2021
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
